Aadi Bioscience (AADI)
(Delayed Data from NSDQ)
$1.75 USD
+0.07 (4.17%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
AADI 1.75 +0.07(4.17%)
Will AADI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AADI
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Other News for AADI
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience presents new subgroup analysis in advanced malignant PEComa
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)